by Damon Race | Feb 8, 2022 | In the News
Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...
by Damon Race | Nov 3, 2021 | In the News
Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...
by Damon Race | Nov 2, 2021 | Press
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
by Damon Race | Mar 3, 2021 | Press
March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...
by Damon Race | Feb 5, 2021 | In the News
by WRAL TechWire — January 29, 2021 RESEARCH TRIANGLE PARK – More than 100 startups and emerging entrepreneurial companies will participate in the Venture Connect 2021 summit, the Council for Entrepreneurial Development announced today. The event is set for March...
Recent Comments